Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06683014 · ClinicalTrials.gov registry record · Phase 2
MDMA in Borderline Personality Disorder
A Phase 2 study of Borderline Personality Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06683014 is a Phase 2 study of Borderline Personality Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 10 participants, below the 107-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06683014, a Phase 2 study of Borderline Personality Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
Conditions Studied
Interventions
- DRUG MDMA
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06683014
The ClinicalTrials.gov registry entry for NCT06683014 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which MDMA is the first listed.
NCT06683014 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06683014 about?
NCT06683014 is a clinical study titled "MDMA in Borderline Personality Disorder". The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
What is the current status of trial NCT06683014?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-05. Estimated completion is 2026-09.
What conditions does trial NCT06683014 study?
This clinical trial studies the following conditions: Borderline Personality Disorder.
What interventions are being tested in trial NCT06683014?
The interventions under investigation include: MDMA (DRUG).
Who is sponsoring clinical trial NCT06683014?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06683014 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
RECRUITING · Phase 2
-
Treatment of Suicidal Women With Borderline Personality Disorder
COMPLETED · Phase 2
-
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
COMPLETED · Phase 2
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.